Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ALNY
  • CUSIP: 02043Q10
  • Web:
  • Market Cap: $10.43926 billion
  • Outstanding Shares: 91,733,000
Average Prices:
  • 50 Day Moving Avg: $81.14
  • 200 Day Moving Avg: $69.12
  • 52 Week Range: $31.38 - $118.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.59
  • P/E Growth: -0.47
Sales & Book Value:
  • Annual Revenue: $66 million
  • Price / Sales: 158.17
  • Book Value: $12.25 per share
  • Price / Book: 9.29
  • EBIDTA: ($436,510,000.00)
  • Net Margins: -670.81%
  • Return on Equity: -45.53%
  • Return on Assets: -34.43%
  • Debt-to-Equity Ratio: 0.13%
  • Current Ratio: 8.84%
  • Quick Ratio: 8.84%
  • Average Volume: 889,150 shs.
  • Beta: 2.97
  • Short Ratio: 11.01

Frequently Asked Questions for Alnylam Pharmaceuticals (NASDAQ:ALNY)

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its earnings results on Wednesday, August, 9th. The company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.22) by $0.12. The firm had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company's quarterly revenue was up 82.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.05) EPS. View Alnylam Pharmaceuticals' Earnings History.

When will Alnylam Pharmaceuticals make its next earnings announcement?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Alnylam Pharmaceuticals.

Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?

20 equities research analysts have issued 1-year target prices for Alnylam Pharmaceuticals' stock. Their forecasts range from $50.00 to $146.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $96.35 in the next twelve months. View Analyst Ratings for Alnylam Pharmaceuticals.

What are analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

  • 1. Chardan Capital analysts commented, "We reiterate: Ionis is part of our open pair trade that is long Alnylam and short Ionis.) We believe the positive patisiran safety and efficacy data should be considered positive for other players in the RNAi space, including Buy-rated Arbutus Biopharma, which will receive royalties on potential sales of patisiran." (9/25/2017)
  • 2. Needham & Company LLC analysts commented, "Alnylam announced today that dosing of fitusiran, in development for Hemophilia, has been suspended in all clinical trials. A patient death tied to a thrombotic event was reported in ongoing Phase 2 OLE trial and FDA has issued a clinical hold. Alnylam had just initiated a Phase 3 program in Jul 2017. The incident raises questions around safety margin for the drug. Fitusiran is intended to increase thrombin levels closer to normal range. Concerns, however, have been raised around risk of thrombosis if thrombin levels are too high, particularly when used w/ on-demand factor or bypassing agents. Based on available clinical data, we believe fitusiran allows for better control of Hemophilia, but patients and physicians may have a narrower safety window when managing bleeds. Our bias is Alnylam and FDA will reach agreement on a protocol to more closely monitor patients and that clinical development will resume over next 3-6 months. We continue to believe in long-term value of RNAi, but acknowledge greater risk than we anticipated around fitusiran. We have reduced our fitusiran estimates to reflect delayed launch and slower market penetration." (9/7/2017)
  • 3. According to Zacks Investment Research, "Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance two additional programs into late-stage trials in 2017 and already commenced a phase III study for one of its candidates-fitusiran in July 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning." (7/17/2017)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:

  • Michael W. Bonney, Independent Chairman of the Board
  • Barry E. Greene, President
  • John M. Maraganore Ph.D., Chief Executive Officer, Director
  • Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer
  • Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President
  • Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development
  • Laurie B. Keating, Senior Vice President, General Counsel, Secretary
  • Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
  • Theresa Heggie, Senior Vice President, Head of Europe and Canada
  • Peter F. Smith Ph.D., Senior Vice President - Early Development

Who owns Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.92%), Dodge & Cox (10.66%), Vanguard Group Inc. (7.45%), BlackRock Inc. (6.02%), Baillie Gifford & Co. (3.98%) and State Street Corp (2.11%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, David E I Pyott, David-Alexandre C Gros, John Maraganore, Kevin P Starr, Laurie Keating, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., State Street Corp, Dodge & Cox, Balyasny Asset Management LLC, Rockefeller Financial Services Inc., Wells Fargo & Company MN, Tekla Capital Management LLC and Pictet Asset Management Ltd.. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, Barry E Greene, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Janus Henderson Group PLC, BlackRock Inc., TIAA CREF Investment Management LLC, PDT Partners LLC, Farallon Capital Management LLC and Broadfin Capital LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Laurie Keating, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy Alnylam Pharmaceuticals stock?

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $113.80.

MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  653 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  887
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 5 Hold Ratings, 12 Buy Ratings
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $96.35 (15.33% downside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017Jefferies Group LLCReiterated RatingBuy$102.00N/AView Rating Details
9/25/2017Chardan CapitalReiterated RatingBuy$124.00LowView Rating Details
9/22/2017BMO Capital MarketsReiterated RatingOutperform$99.00 -> $134.00LowView Rating Details
9/21/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$90.00 -> $146.00LowView Rating Details
9/21/2017Sanford C. BernsteinReiterated RatingOutperform -> Buy$94.00 -> $135.00LowView Rating Details
9/20/2017Stifel NicolausReiterated RatingHold$56.00 -> $83.00LowView Rating Details
9/20/2017Cowen and CompanyReiterated RatingOutperform$93.00 -> $117.00LowView Rating Details
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$110.00 -> $116.00LowView Rating Details
9/20/2017Needham & Company LLCBoost Price TargetBuy -> Buy$85.00 -> $125.00LowView Rating Details
9/20/2017JMP SecuritiesBoost Price TargetOutperform$101.00 -> $128.00LowView Rating Details
9/15/2017InstinetInitiated CoverageReduce -> Reduce$56.00LowView Rating Details
9/14/2017NomuraInitiated CoverageReduce$56.00HighView Rating Details
9/8/2017Leerink SwannReiterated RatingMarket Perform$83.00 -> $72.00LowView Rating Details
9/7/2017Barclays PLCReiterated RatingEqual Weight -> Overweight$80.00 -> $105.00HighView Rating Details
8/11/2017Credit Suisse GroupReiterated RatingBuy$96.00LowView Rating Details
8/10/2017Morgan StanleyBoost Price TargetEqual Weight$46.00 -> $50.00MediumView Rating Details
6/26/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
6/2/2017Janney Montgomery ScottInitiated CoverageUnderperform -> Sell$69.70 -> $67.00LowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$44.00 -> $64.00MediumView Rating Details
3/20/2017FBR & CoReiterated RatingBuyHighView Rating Details
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 9/26/2015 forward)


Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings History by Quarter for Alnylam Pharmaceuticals (NASDAQ ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($1.26)N/AView Earnings Details
8/9/2017Q2 2017($1.22)($1.34)$23.86 million$15.93 millionViewListenView Earnings Details
5/5/2017Q1 2017($1.22)($1.25)$22.91 million$19.00 millionViewN/AView Earnings Details
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.65)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.66)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.54)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($1.18)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
2017 EPS Consensus Estimate: ($4.93)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.30)($1.33)
Q2 20172($1.20)($1.15)($1.18)
Q3 20172($1.25)($1.18)($1.22)
Q4 20172($1.32)($1.10)($1.21)
(Data provided by Zacks Investment Research)


Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 94.25%
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2017Barry E GreenePresidentSell76,815$100.00$7,681,500.00View SEC Filing  
5/31/2017SanofiMajor ShareholderBuy297,501$71.87$21,381,396.87View SEC Filing  
5/30/2017Laurie KeatingSVPBuy11,500$65.35$751,525.00View SEC Filing  
5/23/2017Akshay VaishnawEVPSell11,000$75.00$825,000.00View SEC Filing  
5/16/2017Michael MasonVPSell9,375$70.00$656,250.00View SEC Filing  
5/15/2017Akshay VaishnawSVPSell43,750$65.00$2,843,750.00View SEC Filing  
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.35View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateHeadline logoChardan Capital Reaffirms "Buy" Rating for Alnylam Pharmaceuticals, Inc. (ALNY) - September 25 at 9:04 AM logoFY2018 Earnings Estimate for Alnylam Pharmaceuticals, Inc. Issued By Leerink Swann (ALNY) - September 25 at 8:38 AM logoAlnylam Pharmaceuticals Target of Unusually High Options Trading (ALNY) - September 23 at 1:02 AM logoAlnylam Pharma Up 50% After Positive Phase 3 Results - September 22 at 7:47 PM
News IconBRIEF-Alnylam's genetic disease drug meets main goal in phase 3 study - September 22 at 7:47 PM logoAlnylam Pharmaceuticals Inc. (ALNY) Soared To A New High On Study Results - September 22 at 7:47 PM logoAlnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up - September 22 at 7:47 PM logoAlnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALNY-US : September 21, 2017 - September 22 at 7:47 PM logoAlnylam Pharmaceuticals CEO: Trial results open up the do... - September 22 at 7:47 PM logoAlnylam Pharmaceuticals: Bet or Fold? - September 22 at 7:47 PM logoInsider Selling: Alnylam Pharmaceuticals, Inc. (ALNY) President Sells 76,815 Shares of Stock - September 22 at 7:30 PM logoAlnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session - Nasdaq - September 22 at 2:45 PM logoAlnylam Pharmaceuticals: Bet or Fold? - Barron's - September 22 at 2:45 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Earns "Outperform" Rating from BMO Capital Markets - September 22 at 9:18 AM logoContrasting Regulus Therapeutics (RGLS) and Alnylam Pharmaceuticals (ALNY) - September 22 at 9:02 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Earns "Buy" Rating from Ladenburg Thalmann Financial Services - September 21 at 7:35 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Given New $12.00 Price Target at Barclays PLC - September 21 at 1:18 PM logoSanford C. Bernstein Reiterates "Positive" Rating for Alnylam Pharmaceuticals, Inc. (ALNY) - September 21 at 10:02 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Receives Outperform Rating from Credit Suisse Group - September 21 at 10:02 AM logoLeerink Swann Reiterates "Hold" Rating for Alnylam Pharmaceuticals, Inc. (ALNY) - September 21 at 8:52 AM logoMid-Afternoon Market Update: Crude Oil Up Over 2%; Alnylam Pharma Shares Climb After Positive Phase 3 Results - Nasdaq - September 20 at 8:40 PM logoAlnylam's patisiran successful in late-stage ATTR study - Seeking Alpha - September 20 at 8:40 PM logoArbutus Biopharma (ABUS) and Alnylam Pharmaceuticals, Inc. (ALNY) Reports Positive Phase 3 Results for LNP ... - - September 20 at 8:40 PM logoWhy Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today - Motley Fool - September 20 at 8:40 PM logoPiper Jaffray Companies Reaffirms "Overweight" Rating for Alnylam Pharmaceuticals, Inc. (ALNY) - September 20 at 8:20 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Receives "Hold" Rating from Stifel Nicolaus - September 20 at 8:20 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Cowen and Company - September 20 at 8:20 PM logoNeedham & Company LLC Increases Alnylam Pharmaceuticals, Inc. (ALNY) Price Target to $125.00 - September 20 at 6:58 PM logoJMP Securities Boosts Alnylam Pharmaceuticals, Inc. (ALNY) Price Target to $128.00 - September 20 at 4:32 PM logoAlnylam Pharmaceuticals Inc. (ALNY) Has Jumped To A New High On Study Results - September 20 at 3:37 PM logoAlnylam shares surge 40% on drug results that may herald a new type of medicine - September 20 at 3:37 PM logoAlnylam's RNAi drug clears key study, shares soar - September 20 at 3:37 PM logoCalamities Couldn't Spoil The Bullish Run - September 20 at 3:37 PM logoCheer Alnylam's Drug, Pause on Its Platform - September 20 at 3:37 PM logoAfter 20 Years, A Drug That Silences Genes Succeeds - September 20 at 3:37 PM logoWhat's Next for Alnylam Pharmaceuticals, Inc.? - September 20 at 3:37 PM logoAlnylam Rockets On Strong Rare-Disease Drug Data; Ionis Tanks - September 20 at 3:37 PM logoAlnylam's RNAi drug succeeds in key study, shares soar - September 20 at 3:37 PM logoWhy Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today - September 20 at 1:43 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough - September 20 at 1:19 PM logoAlnylam On Its Back Foot Heading Into A Major Event - Seeking Alpha - September 19 at 3:45 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Earns "Buy" Rating from Jefferies Group LLC - September 18 at 5:45 PM logoBillionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You? - September 18 at 4:11 PM logoNomura bearish on Alnylam; sees 28% downside risk - Seeking Alpha - September 16 at 2:18 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Research Coverage Started at Instinet - September 15 at 6:46 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Coverage Initiated at Nomura - September 14 at 11:06 PM logoAlnylam Pharmaceuticals' (ALNY) CEO John Maraganore Presents at Morgan Stanley Global Healthcare Conference ... - Seeking Alpha - September 13 at 4:51 PM logoBiotech Gets More Forgiving, But Riskier - September 13 at 4:51 PM logoReviewing RXi Pharmaceuticals Corporation (RXII) and Alnylam Pharmaceuticals (ALNY) - September 11 at 4:10 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Earns Buy Rating from Chardan Capital - September 11 at 8:10 AM



Alnylam Pharmaceuticals (ALNY) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by Staff